Entera Bio (NASDAQ:ENTX) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Key Points

• Entera Bio reported quarterly earnings of $0.07 per share, beating Wall Street’s estimate of -$0.08 by $0.15.
• The stock fell 5.1% on Friday to about $1.30, remaining well below its 52-week high of $3.22.
• Insiders have been buying shares recently, including Director Geno J. Germano, who purchased 20,000 shares, while analysts currently have a Hold consensus with a $9.00 price target.

Entera Bio (NASDAQ:ENTX - Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.15, FiscalAI reports.

Entera Bio Trading Down 5.1%

NASDAQ:ENTX traded down $0.07 during trading hours on Friday, hitting $1.30. 158,026 shares of the stock were exchanged, compared to its average volume of 213,942. Entera Bio has a 52-week low of $0.91 and a 52-week high of $3.22. The firm's fifty day moving average price is $1.23 and its 200 day moving average price is $1.73. The company has a market cap of $60.61 million, a P/E ratio of -5.00 and a beta of 1.54.

Insider Buying and Selling

In other news, Director Geno J. Germano acquired 20,000 shares of the business's stock in a transaction on Monday, March 9th. The stock was bought at an average cost of $1.30 per share, for a total transaction of $26,000.00. Following the purchase, the director owned 40,000 shares in the company, valued at approximately $52,000. This represents a 100.00% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders purchased 58,000 shares of company stock worth $72,620. 10.38% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Entera Bio

Several large investors have recently bought and sold shares of ENTX. Citadel Advisors LLC increased its stake in Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company's stock worth $77,000 after buying an additional 28,322 shares in the last quarter. HighTower Advisors LLC increased its stake in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company's stock worth $84,000 after buying an additional 25,000 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Entera Bio by 22.2% in the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company's stock valued at $210,000 after purchasing an additional 19,601 shares in the last quarter. Jane Street Group LLC grew its position in shares of Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company's stock valued at $144,000 after purchasing an additional 43,536 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its position in shares of Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company's stock valued at $1,157,000 after purchasing an additional 29,629 shares in the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. HC Wainwright cut their price target on Entera Bio from $10.00 to $9.00 and set a "buy" rating for the company in a research note on Monday, April 27th. Weiss Ratings restated a "sell (d-)" rating on shares of Entera Bio in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $9.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company's lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.